Alzheimer Psychosis Agent ACP-204 Shows No Impact on Corrected QT Intervals in Phase 1 Analysis
An analysis of healthy adult participants from a phase 1 trial showed that treatment with ACP-204 (Acadia Pharmaceuticals),…
Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD
WATCH TIME: 6 minutes “I think the implications [of these findings with SPG302] for patients are incredible. This…
Elecsys pTau181 Blood Test Gains European Approval for Alzheimer Disease Diagnosis
According to a new announcement, Roche’s Elecsys pTau181 test, a blood test geared to rule out Alzheimer disease…
Phase 2 Trial of Posdinemab Reveals Racial Differences in Screen Failure for Early Alzheimer Disease
Janice Wong, lead author and senior medical leader in neuroscience at Johnson & Johnson Preliminary data from the…
Nicotinamide Riboside Shows Effects on Hippocampal Features but Not Improved Memory
New data from a 12-week, double-blind, randomized phase 2 trial showed that nicotinamide riboside (NR) supplementation was safe…
MRI Analysis Shows Brain Morphological Changes in Patients With Breast Cancer and Chemotherapy-Related Cognitive Impairment
Paul Edison, MD, PhD (Credit: Imperial College London) A newly presented study involving patients with breast cancer treated…
Behavioral Therapy Noninferior to Solifenacin in Managing Overactive Bladder Symptoms of Parkinson Disease
Camille P. Vaughan, MD, MS (Credit: Emory University) In a newly published 12-week randomized noninferiority trial (NCT03149809), findings…